Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06497413 · ClinicalTrials.gov registry record · NA
Brain Vascular and Neurocognitive Health
A NA study of Alzheimer Disease and Cognitive Decline, sponsored by The University of Texas at Arlington.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06497413: Completed NA study of Alzheimer Disease and Cognitive Decline, sponsored by The University of Texas at Arlington.
NCT06497413 is a NA study of Alzheimer Disease and Cognitive Decline that has completed, run by The University of Texas at Arlington. The registered enrollment target is 24 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06497413, a NA study of Alzheimer Disease and Cognitive Decline, has completed, sponsored by The University of Texas at Arlington.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.
Primary Outcome
This will be assessed as the increase in blood flow in the middle cerebral artery during a hypercapnic stimulus
Conditions Studied
Interventions
- DEVICE Transcranial Photobiomodulation
- DEVICE Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered
Study Locations (1)
Texas
- UT Arlington - Science and Engineering Innovation and Research Building - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2025-09-17 |
| Phase | NA |
What the finished NCT06497413 record still lists
NCT06497413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Transcranial Photobiomodulation is the first listed.
NCT06497413 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06497413 about?
NCT06497413 is a clinical study titled "Brain Vascular and Neurocognitive Health". The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.
What is the current status of trial NCT06497413?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2024-04-16. Estimated completion is 2025-09-17.
What conditions does trial NCT06497413 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Decline, Cognitive Dysfunction, Vascular Disease, Peripheral.
What interventions are being tested in trial NCT06497413?
The interventions under investigation include: Transcranial Photobiomodulation (DEVICE), Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered (DEVICE).
Who is sponsoring clinical trial NCT06497413?
This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06497413 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06497413's enrollment target sits among peer trials
24 258th of 306 higher than 45 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI